Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Phase 3 Results for Olokizumab in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  March 3, 2020

In a recent study, olokizumab proved safe and effective for treating the signs and symptoms of RA and improving patients’ physical function…

Filed under:Drug Updates Tagged with:2019 ACR/ARP Annual MeetingolokizumabRheumatoid Arthritis (RA)

Pearls & Myths: Experts Offer Advice & Dispel Myths

Thomas R. Collins  |  February 25, 2020

GCA, GPA, myositis, new research—rheumatology care keeps clinicians on their toes & requires them to stay up to date…

Filed under:CareerCareer DevelopmentMeeting ReportsProfessional Topics Tagged with:2019 ACR/ARP Annual Meeting

Sodium-Glucose Cotransporter-2 Inhibitors May Decrease Gout Risk in Some Patients

Lara C. Pullen, PhD  |  February 19, 2020

Recent research assessed the risk of gout in patients with type 2 diabetes mellitus prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with those prescribed a glucagon-like peptide-1 (GLP-1) agonist. The study found patients on the SGLT2 inhibitor had a lower rate of gout, suggesting SGLT2 inhibitors may actually reduce the risk of gout among this patient population…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:GoutSGLT2 inhibitorssodium-glucose cotransporter-2 (SGLT2) inhibitorstype II diabetes

Coding Corner Questions: Using NP/PA Services in Practice

From the College  |  February 13, 2020

Scenario 1: Direct Billing A 70-year-old female patient with rheumatoid arthritis in multiple joints and positive rheumatoid factor returns to the practice for her fourth infusion of infliximab with the nurse practitioner (NP). She reports no fevers, cough, dyspnea or concurrent illness. She rates the severity of her joint pain at 6 on a 10-point…

Filed under:Billing/CodingFrom the College Tagged with:Medicarenurse practitionerphysician assistant

FDA Rheumatology Update: New Drug Approvals, Plus Expanded Drug Indications & Safety Concerns

Susan Bernstein  |  February 12, 2020

Last year, the FDA was busy with new biologic and other drug approvals, new and expanded drug indications, and important safety updates relevant to rheumatology…

Filed under:Drug Updates Tagged with:2019 ACR/ARP Annual MeetingBiologicsFDAU.S. Food and Drug Administration (FDA)

Remembering Etanercept & the Advent of the Biologic Era

Robert S. Katz, MD  |  February 10, 2020

As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…

Filed under:Biologics/DMARDsSpeak Out Rheum Tagged with:etanerceptSpeak Out Rheumatology

Canada & E.U. Approve Upadacitinib for RA

Michele B. Kaufman, PharmD, BCGP  |  January 28, 2020

Upadacitinib will soon be available to treat patients with moderate to severe rheumatoid arthritis in Canada and the E.U…

Filed under:Biologics/DMARDsDrug Updates Tagged with:CanadaEuropean UnionRheumatoid Arthritis (RA)U.S. Food and Drug Administration (FDA)upadacitinib

The Care & Treatment of Myositis: Creatinine Kinase Level Isn’t Gospel & Other Recommendations

Thomas R. Collins  |  January 28, 2020

During a session at the 2019 ACR/ARP Annual Meeting, Lisa Christopher-Stine, MD, MPH, provided valuable recommendations and practical insights into the care and treatment of myositis patients…

Filed under:ConditionsMyositis Tagged with:2019 ACR/ARP Annual MeetingmyositisTreatment

New Insights into the Management of Giant Cell Arteritis

Lara C. Pullen, PhD  |  January 28, 2020

A systematic literature review identified novel evidence on the treatment and management of GCA that was incorporated into the most recent EULAR recommendations on the management of large vessel vasculitis. Investigators confirmed the efficacy of prompt initiation of glucocorticoids and found fast-track approaches to diagnosis lowered the risk of ischemic complications…

Filed under:ConditionsEULAR/OtherMeeting ReportsVasculitis Tagged with:EULARGCAgiant cell arteritis (GCA)guidelinelarge-vessel vasculitisrecommendationstocilizumab

Tips for Exploring Tough Topics with Teens with Rheumatic Disease

Susan Bernstein  |  January 17, 2020

ATLANTA—Managing teenage patients may present challenges for pediatric rheumatologists and rheumatology professionals not only because of their often complex, rare conditions, but because teenagers are, well, teenagers. Teens may experiment with sexual intercourse, alcohol use, tobacco or vaping e-cigarettes to fit in with their peers, even if these habits have serious health consequences, according to…

Filed under:Patient PerspectivePresident's Perspective Tagged with:2019 ACR/ARP Annual MeetingLGBTQPediatric Rheumatology

  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 105
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences